Call Us: 1.800.873.5297

By

NuvaRing® Drug Information

nuvaringNuvaRing® is the trade name for a vaginal contraceptive ring manufactured by Organon, a company now owned by Schering-Plough, Inc. NuvaRing® is the first and only vaginal birth control ring. It was approved by the Food and Drug Administration (FDA) in 2001. Since that time, there have been reports of many serious side effects in users of NuvaRing®, including pulmonary embolism, deep vein thrombosis, strokes, and heart attacks.

What is NuvaRing®?

NuvaRing® is a vaginal plastic ring that remains in the vagina for three weeks. The ring is removed on the fourth week. During this three-week period, the ring continuously releases two different types of hormones into a woman’s body. These hormones include ethinyl estradiol (synthetic estrogen) and etonogestrel (a progestin or artificial progestagen, another hormone). Etonogestrel is considered a third-generation progestin, which has been associated with a greater risk for developing blood clots than the type of artificial progestagen used in other hormonal birth controls. Etonogestrel is proprietary to Organon, now a subsidiary of Schering-Plough, which is soon to be acquired by Merck, and is used only in NuvaRing® and their implant birth control method, Implanon.

NuvaRing® Dangers

There are a number of dangerous side effects being reported by women after using NuvaRing® birth control. These side effects include:

  • Deep vein thrombosis (blood clots most often occurring in the legs, arms and pelvis)
  • Pulmonary embolism (a blood clot in the lungs)
  • Strokes
  • Heart attack

NuvaRing® Lawsuits

Numerous lawsuits have already been filed by women who have suffered serious side effects while using NuvaRing®. You may also be eligible for compensation. Please contact us to schedule a NuvaRing® lawsuit consultation with the pharmaceutical injury lawyers at Schlichter, Bogard & Denton today. The US District Court in St. Louis is the venue for the multidistrict litigation for Nuvaring®, and Schlichter, Bogard & Denton attorneys have a lead role in handling this litigation.

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.